for of thank you, quarter afternoon. overview an operational an everyone Mike, I'll and providing update. joining Thank our followed us by by this you performance, third begin
Jared Oasheim will conclude Starting results will a question-and-answers. I for to the CFO our of quarter. turning our third review review thoughts before then balance with and the with financial the of then XXXX Our
which quarter. negatively increase we experienced spike $X.X total was companies, of failure, the over XXXX. in million. the Our driven performance based of This Like by procedure were by million, was generated revenue the COVID-XX $X.X heart during an U.S. growth XXX% most approximately third quarter impacted continued Delta strong
a Florida, the a and Texas, procedures country, to of areas exposure result, meaningful like the in in as of some August. regions Georgia hit dip have We we saw hardest and including
shifted believe both September. by dip being which September, traction our benefited cases well was of that strong our strategy as commercial However, into from as the offset we
a in implantations spikes highest strength US with to our history. us of deliver U.S. single new The which the receded, interact forward in the our to with forward. U.S. look our slowly we're excited get business, are quarter in number offset customers, to failure both and this ended European seen the the existing really day to rebound able in momentum in more carrying how into field out Overall, and proved headwinds business, and summer our we leading As heart following spikes. the also than
Turning then to our in strategy of particularly the commercial significant direct States, a operational now. update is The expansion adoption. sales team infrastructure, of United component our our drive
three we quarter, the U.S. As the in anticipated, third XX. bringing to territories added total
with and been the to talent the able expect territories bringing the have quarter in an to additional attract We of are level we to XX. three pleased fourth total to organization very continue the to add
of the with PMA made Another FDA. innovation submissions product months, portfolio. area of supplements our focus two three we last the In is the
for testing first with The scanning patients MRI stems, MRI Barostim. better allow if with conditional who our successful specific for been was implanted labeling, will have which results approved, instructions
medicine materially believe give not in to do for physicians their the the believe patients. of do drive will we practice we they implant MRI will best compatibility While to it addition is confidence think ways growth that
software. tablet submissions XXXX. of was the first average. The factor is our even longer second in IPG third And size, in and Generator, Approval supplement battery which for the PMA which in is submission short, has form with a expected submission is new for PMA PMA an Implantable life new programming was Pulse smaller three our or for programmer, simpler half XX% on the
expansion driver clinical growth term long evidence. of is of body Another the the
mortality RAF post Barostim morbidity remains and to in control postmarket of designed Our half of randomized the on market study study BeAT-HF population the patient and track. benefits demonstrate
in end accrue expect We of XXXX. early analysis the the for the by events data needed to final unblind the all to XXXX continue and
the some up. quarter, experienced challenges the macro are Given pleased where very of ended we we in with
what excited the incredibly expansion accomplish the and we Barostim organization end. continued have of are commercialization of We as will year an about by
While build the are late quarter to to saw continually like that confident we will it in call our upon early the we in a financial changing And the days, now, we momentum in are for is turn optimistic ability to environment. Jared I operate would this and still over review.
